# A Phase II Study of M2951 in SLE

> **NCT02975336** · PHASE2 · TERMINATED · sponsor: **EMD Serono Research & Development Institute, Inc.** · enrollment: 469 (actual)

## Conditions studied

- Systemic Lupus Erythematosus

## Interventions

- **DRUG:** Placebo
- **DRUG:** M2951
- **DRUG:** M2951
- **DRUG:** M2951
- **DRUG:** M2951

## Key facts

- **NCT ID:** NCT02975336
- **Lead sponsor:** EMD Serono Research & Development Institute, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2017-01-04
- **Primary completion:** 2019-11-27
- **Final completion:** 2020-03-23
- **Target enrollment:** 469 (ACTUAL)
- **Why stopped:** Study is completed; primary analysis completed.
- **Last updated:** 2021-04-12

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02975336

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02975336, "A Phase II Study of M2951 in SLE". Retrieved via AI Analytics 2026-09-08 from https://api.ai-analytics.org/clinical/NCT02975336. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*